Objective. To determine the prevalence of asymptomatic cardiac involvement and its correlation with noncardiac manifestation in Thai SSc patients.
Introduction
Cardiac involvement is one of the most serious internal organ involvements and the leading cause of death in SSc patients [1, 2] -prevalence 14% by clinical observation [1] and higher by autopsy [3, 4] . Many SSc patients with cardiac involvement are asymptomatic or underdiagnosed [5, 6] . The condition may progress silently to overt clinical manifestations, including systolic and/or diastolic dysfunction, myocardial ischaemia, myocardial hypertrophy, heart failure, pericardial effusion and arrhythmias. Early detection of cardiac abnormalities is therefore very important.
Several techniques are used to detect silent cardiac abnormalities in SSc patients, such as MRI [7, 8] , nuclear imaging and SPECT [911] ); however, these are expensive, require specialist skills in interpretation and are not widely available in clinical practice.
All SSc patients are recommended to undergo echocardiography (ECHO) annually [6, 12] . It is a non-invasive technique used to identify changes due to early pulmonary hypertension, to assess myocardial dysfunction partly due to myocardial fibrosis and reducing myocardial perfusion, and for detection of pericardial effusion [13] .
Many aspects of cardiac involvement in SSc patients have been reported, including: evaluation with MRI (or combination of MRI and ECHO) in symptomatic SSc patients [12, 13] ; ECHO evaluation of asymptomatic SSc patients [5, 14, 15] ; and assessment of atherosclerotic risk factors [8, 13, 16] . There are, however, no published data on the prevalence of cardiac abnormalities in asymptomatic SSc patients using a combination of non-invasive and non-expensive screening tools [i.e. ECG, chest radiography (CXR), ECHO and cardiac markers] We, therefore, aimed to investigate the prevalence and clinical correlation of silent cardiac involvement in asymptomatic SSc patients using these screening tools. Long-term follow-up is planned for further study in order to evaluate the natural history and clinical outcome of these abnormalities.
Methods
Between 1 January 1 2012 and 30 June 2013, a crosssectional study of Thai adult patients with SSc was conducted at Srinagarind Hospital, Khon Kaen University, Thailand. Patients were eligible if they were >18 and had a diagnosis of SSc based on the ACR criteria [17] with WHO functional class I. The disease subtype was classified according to LeRoy et al. [18] . Patients with signs or symptoms suggestive of cardiac involvement or having any previous cardiac problems were not included. We excluded those having a diagnosis of SSc overlapping with other CTD, serum creatinine >123.8 mmol/l, a WHOfunctional class of IIIV, cardiac chest pain, heart failure, arterial hypertension, the presence of any atherosclerosis risk factors (diabetes mellitus, dyslipidaemia, family history of coronary heart disease, stroke, smoking) or having a history of heart disease (including congenital heart disease, coronary heart disease, valvular heart disease, cardiomyopathy or previous heart operation).
Patients with severe co-morbid diseases (i.e. cancer or sepsis) and taking angiotensin-converting enzyme inhibitors or diuretics were also excluded. The study was approved by the Human Research Ethics Committee at Khon Kaen University as per the Declaration of Helsinki and the Good Clinical Practice Guidelines (HE541335). Written informed consent was obtained from all patients.
Non-invasive tests for cardiac involvement were performed in a single visit, including: ECG, CXR, ECHO, creatine kinase (CK) and CK-MB subunit, high sensitive cardiac troponin-T (hs-cTnT) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP). ECG and ECHO were assessed by the same cardiologist. ECHO was performed using an Aloka ProSound F75 or Aloka ProSound a10 sonographic system (Hitachi-Aloka Medical Ltd, Tokyo, Japan). Haemodynamic parameters recorded included tricuspid regurgitation flow and velocity, right ventricular systolic pressure, right atrial pressure, left ventricular ejection fraction and left ventricular E/e 0 ratio.
Operational definitions
Cardiac involvement was defined when the patient had at least one of these abnormalities: cardiomegaly, elevation of hs-cTnT or cardiac enzymes, conduction defects demonstrated by ECG included atrioventricular block, prolonged distance between a Q wave and T wave in an ECG (QT interval), complete bundle branch block, and cardiac arrhythmia or abnormal ECHO findings. Cardiomegaly was defined as when the cardiothoracic ratio from CXR or CT of chest is more than 0.5. A high CK-MB and high ESR were defined when the serum CK-MB and the ESR rose above 25 U/l and 25 mm/h, respectively. A respective high-sensitivity CRP (hsCRP) and hs-cTnT (Roche Diagnostics) were defined when the hsCRP level was >5.0 mg/dl and 0.014 ng/ml (which for the latter exceeds the reference limit for the 99th percentile) [19, 20] . A prolonged QT interval was defined as >440 ms in men and >460 ms in women [21] . Elevated cardiac enzyme was defined when either hs-cTnT or CK-MB were elevated. Left ventricular diastolic function is determined by the ratio of peak E to peak A velocity (E/A) as measured by pulsed-wave Doppler of mitral inflow; tissue Doppler longitudinal velocity of the septal mitral annulus (e 0 ); and the ratio of mitral peak E velocity to e 0 velocity (E/e 0 ratio). We followed the American Society of Echocardiography Guidelines [22] , so diastolic dysfunction was diagnosed if septal e 0 velocity <8 cm/s, while the E/A ratio and E/e 0 ratio indicated the severity of dysfunction. The cut-off for the NT-proBNP level was by age group: high NT-proBNP was defined as >450 pg/ml in persons under 50 years of age, >900 pg/ml in those between 50 and 75, and >1800 pg/ml in those over 75 years [23] . NT-proBNP was tested using Elecsys NT-proBNP (Roche Diagnostics). RP was defined when skin colour changed; throbbing pain, numbness or tingling of the fingers were felt in response to cold; and symptoms disappeared after warming up. Pulmonary fibrosis was defined when interstitial www.rheumatology.oxfordjournals.org fibrosis was detected by either CXR or high resolution CT. Stomach symptoms were defined as early satiety, vomiting or delayed gastric emptying (gastroparesis).
Statistical analysis
The sample size calculation was based on the prevalence of asymptomatic cardiac involvement in SSc patients. According to the formula by Daniel [24] , the sample size should be at least 81 subjects. We, however, planned to recruit 100 subjects to achieve a significance level of 0.10, based on a drop-out rate of 20%.
The prevalence of cardiac involvement and the 95% CI were calculated. The odds ratio (OR) and 95% CI were applied to determine the clinical characteristics associated with asymptomatic cardiac involvement. The chisquare or Fisher exact test was used as appropriate to differentiate between cardiac features in dcSSc and lcSSc. Continuous data were presented as mean (S.D), while categorical data were presented as proportions or percentages. Correlations between the continuous variables were tested using the Spearman's rank correlation or Wilcoxon Sign rank test, as appropriate. Any variable with P < 0.10 was entered into the multiple logistic regression model. Backward elimination was used for model fitting. Variables were tested for significance using the Wald 2 statistic (all statistical tests were two-tailed); P < 0.05 was considered statistically significant. All data analyses were performed using STATA version 11.2 (StataCorp., TX, USA).
Results
A total of 103 SSc patients were enrolled: the female to male ratio was 3:1. The majority (61.2%) had the dcSSc subset. The mean age was 50.6 (11.9) years (range, 19.880.5). The median duration of disease was 4.6 years (interquartile range 2.28.2). Of the 103 patients, 63 had at least one abnormal test: the prevalence of asymptomatic cardiac involvement was 61.2% (95% CI 51.6, 70.7). Silent cardiac abnormalities identified included: diastolic dysfunction (44.7%), elevation of cardiac enzymes (36.9%), cardiomegaly without pericardial effusion (15.8%) and prolonged QT interval (14.6%).
According to the univariate analysis, the associated subclinical cardiac abnormalities were hand deformity (P = 0.001), dcSSc subset (P = 0.01), RP (P = 0.01), lower BMI (P = 0.02), dysphagia (P = 0.02), shorter duration of disease (P = 0.03), higher modified Rodnan skin score (mRSS) (P = 0.03), tendon friction rub (P = 0.03) and telangiectasia (P = 0.04). According to the multivariate analysis, however, the only predictor for asymptomatic cardiac involvement was dcSSc subset (OR = 3.37; 95% CI 1.07, 10.65).
Based on the subgroup analysis, diastolic dysfunction was more frequent in the lcSSc subset (P = 0.04), whereas elevation of cardiac enzymes and prolonged QT interval were prominent in dcSSc. The correlation between rising cardiac enzymes and the clinical manifestations of SSc was tested (Table 1 ). This abnormality was positively correlated with mRSS (OR 1.08; 95% CI 1.02, 1.17 ), but not with other internal organ involvement. It was more common in patients with shorter disease duration (OR 0.78; 95% CI 0.64, 0.95).
The correlation between prolonged QT interval and clinical manifestations was also tested ( Table 2 ). The latter was more common in patients with RP (OR 4.21; 95% CI 1.19, 14.86) and trended in the dcSSc subset, albeit without statistical significance.
Additional analyses revealed a correlation between high hs-cTnT and QT interval (coefficient 0.21; P = 0.04), NTproBNP level (coefficient 0.39; P < 0.001) and tricuspid regurgitation jet maximum velocity (TRVmax) >2.9 (P = 0.02). None of the patients with a high NT-proBNP had a ventricular ejection fraction under 50% (P = 0.74).
Discussion
The overall prevalence of asymptomatic cardiac involvement among Thai patients with SSc was 61.2%: the prevalence was higher in dcSSc (71%) than in lcSSc (45%). The prevalence of the lcSSc subtype was comparable to the ECHO study of Handa et al. [6] (42.1%), but that study did not explore hs-cTnT and NT-proBNP.
The most common cardiac abnormality found in our study was diastolic dysfunction (44.7%), for which the prevalence was slightly lower than in other reports (5070%) [6, 25] . This may be due to variations in patient characteristics and in the diagnostic criteria used in each study. However, when using the criterion significant diastolic dysfunction (E/e 0 > 15), the prevalence was relatively low (5%), which might explain the asymptomatic nature of the study population. The prevalence of diastolic dysfunction in our study was significantly higher in the lcSSc than in the dcSSc subset, in contrast to the report from Hinchcliff et al. [26] , who found a comparable prevalence of diastolic dysfunction in the two subsets. We cannot explain the discrepancy. The postulated mechanism for diastolic dysfunction in SSc was either myocardial fibrosis [2729] or conditions potentially causing ventricular diastolic function, such as advanced age [28] . The prognosis of the diastolic dysfunction remains unclear; hence, longitudinal investigations are warranted.
Elevation of cardiac enzymes reflecting myocardial injury was demonstrated in one-third of our study. A variety of aetiologies has been postulated; including coronary microcirculation dysfunction [30] or autoimmune myocarditis [31] , without any relation to epicardial coronary artery disease [3] . Seven of our patients had coexisting elevated cardiac enzyme and a prolonged QT interval; five of these patients also had a high ESR. Importantly, the study population had already been screened for (and excluded of) any atherosclerotic risk factors that could lead to coronary artery disease-induced myocardial injury. This observation suggests that inflammation plays some role in myocarditis among SSc patients; however, the correlation between the inflammatory markers (ESR and hsCRP) and the cardiac enzymes was not definitive in the current study. Unfortunately, MRI-which is a sensitive noninvasive tool for detection of subendocardial perfusion defect [32] , myocardium fibrosis [33] and subclinical myocardial inflammation [34] -was not performed in our study, so myocarditis cannot be confirmed, and information regarding the aetiology of myocarditis is inevitably lacking.
The association between rising cardiac enzymes and disease severity, prolonged QT interval and vasculopathy were noted at the early phase of disease. It would be interesting to see whether an intervention that could slow disease progression or mitigate the vasculopathy could also improve myocardial injury among SSc patients. A prolonged QT interval was the most common abnormal ECG finding in the current study, which might be the result of myocardial fibrosis [35] and could progress to ventricular tachycardia, one of the most serious arrhythmias with a high fatality rate leading to sudden death in SSc patients [36, 37] . The prevalence of ventricular tachycardia among patients with a prolonged QT interval was not established in this study, but needs to be closely monitored during long-term follow-up.
NT-proBNP is produced in response to ventricular wall stretching in pressure overload or volume overload to either ventricle, including ventricular dysfunction or pulmonary hypertension [35] . The NT-proBNP level was correlated with elevation of cardiac enzymes and a TRVmax >2.9 m/s in our SSc patients. It can be concluded that some of our patients had either myocardial injury or asymptomatic pulmonary hypertension, which may progress to severe myocardial dysfunction and eventually heart failure. Unfortunately, since all of the patients were asymptomatic, invasive right heart catheterization was unable to proceed to prove the existence of ventricular dysfunction or pulmonary hypertension.
The current study had a few limitations. First, financial limitations ruled out the use of known non-invasive and sensitive tools to demonstrate myocardium lesions (i.e. cardiac MRI or nuclear imaging). Second, the study aimed to explore the prevalence of asymptomatic cardiac involvement in SSc patients, thus differentiation of clinical and laboratory features from SSc patients with established cardiac involvement could not be made. Third, because our study was started before the setting of the 2013 ACR/EULAR classification criteria for SSc, some patients who were diagnosed with SSc by the 2013 ACR/EULAR classification criteria were not included in our study.
The strengths of this study include: use of non-invasive and suitable parameters of cardiac involvement (i.e. cardiac enzymes, ECG and inflammatory biomarkers), giving possible clues to the initiating events in the pathogenesis of cardiac involvement in SSc; the abnormalities found should be directly related to the disease because the conditions influencing cardiac function and coronary diseases were already excluded; and, these preliminary data provide feasible parameters that can be adopted in daily practice to evaluate early cardiac involvement in SSc patients. A longitudinal study of these abnormalities, along with clinical outcome monitoring, is fundamental for better care and improved survival of SSc patients.
Conclusion
The high prevalence of asymptomatic cardiac involvement among Thai patients with SSc was established. The two most common abnormalities were diastolic dysfunction and elevation of cardiac enzymes, which were correlated with the dcSSc subtype, with higher mRSS, and with shorter disease duration. One-third of the patients had elevated cardiac enzymes, possibly from early myocardial microcirculation disruption. Long-term follow-up of these patients is being performed to elucidate the clinical implications of these silent cardiac abnormalities.
